Fortress Biotech, Inc. (FBIO) EPS Estimated At $-0.57

March 14, 2018 - By Kurt Siggers

 Fortress Biotech, Inc. (FBIO) EPS Estimated At $ 0.57

Analysts expect Fortress Biotech, Inc. (NASDAQ:FBIO) to report $-0.57 EPS on March, 15.They anticipate $0.14 EPS change or 32.56 % from last quarter’s $-0.43 EPS. After having $-0.67 EPS previously, Fortress Biotech, Inc.’s analysts see -14.93 % EPS growth. The stock increased 6.41% or $0.32 during the last trading session, reaching $5.31. About 492,420 shares traded or 216.55% up from the average. Fortress Biotech, Inc. (NASDAQ:FBIO) has risen 52.16% since March 14, 2017 and is uptrending. It has outperformed by 35.46% the S&P500.

Fortress Biotech, Inc. (NASDAQ:FBIO) Ratings Coverage

Among 3 analysts covering Fortress Biotech (NASDAQ:FBIO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fortress Biotech had 8 analyst reports since July 11, 2017 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, December 5. The firm earned “Buy” rating on Thursday, August 10 by H.C. Wainwright. The firm has “Buy” rating given on Tuesday, July 11 by H.C. Wainwright. The stock has “Buy” rating by H.C. Wainwright on Tuesday, December 12. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, September 27. As per Tuesday, January 2, the company rating was maintained by H.C. Wainwright.

Fortress Biotech, Inc., a biopharmaceutical company, engages in dermatology product sales, pharmaceutical, and biotechnology businesses in the United States. The company has market cap of $268.99 million. The firm offers CNDO-109, a lysate that activates donor natural killer cells to treat cancer-related and other conditions; tramadol HCl, an intravenous formulation for moderate to moderately severe post-operative pain; CAEL-101 for AL amyloidosis; and CEVA101, which is in Phase II clinical study for severe traumatic brain injury in pediatric patients and adults. It currently has negative earnings. It also provides novel, non-chemotherapy, and immune-enhanced combination treatments for patients with solid tumor cancers; Uracil Topical Cream that is in Phase II to treat and prevent hand-foot syndrome; candidate CUTX-101, a copper histidinate injection for Menkes disease and related copper transport disorders; and novel agents for rare, neglected, or orphan disorders.

More recent Fortress Biotech, Inc. (NASDAQ:FBIO) news were published by: which released: “Fortress Biotech to Present at Oppenheimer’s 28th Annual Healthcare Conference” on March 13, 2018. Also published the news titled: “Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research …” on February 26, 2018.‘s news article titled: “Mustang Bio to Present at the 255th American Chemical Society National Meeting …” with publication date: March 12, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.